EGFR and non-small cell lung carcinoma: For example, in non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (EGFR TKI) have shown high efficiency in the EGFR mutated subpopulation and have led to improved progression-free and overall survival (reviewed in [7]).